Denileukin diftitox: a concise clinical review

Denileukin diftitox (DAB(389)IL-2; Ontak (R)) Is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma. It consists of fragments of diphtheria toxin linked to human Interleukin-2 and works by targeting the high-affinity Interleukin-2 receptor expressed on malignant cells. This article will review the clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma, and discuss the potential future role of this novel drug In patients with both malignant and nonmalignant diseases, Including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, solid tumors, psoriasis and graft-versus-host disease.